Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAPAGREFFE
2023-506295-26-00Phase 4Completed
- Sponsor
- Centre Hospitalier Universitaire de Montpellier
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dapagliflozin in chronic kidney disease (CKD) and Kidney allograft status (RTx) (2 arms), sponsored by Centre Hospitalier Universitaire de Montpellier. Started Oct 2023; status: completed.
02
Drugs
dapagliflozin
03
Conditions
chronic kidney disease (CKD)Kidney allograft status (RTx)
Beyond the preview
Go deeper on 2023-506295-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506295-26-00.